

MONDAY, 9 MAY 2011

	ESTRO Anniversary Track	ESTRO Anniversary track
08:00 – 08:45 Symposia	<p>30 years of radiation oncology in Head & Neck cancer - What is the evidence that 'we' have created?</p> <p>Update of meta-analyses and EBM level 1 on Fractionation P. Blanchard (FR)</p> <p>Update of meta-analyses and EBM level 1 on Hypoxia J. Overgaard (DK)</p> <p>Update of meta-analyses and EBM level 1 on Concomitant and induction chemotherapy J. Bourhis (FR)</p>	<p>ESTRO-ESSO Joint session</p> <p>30 years of radiation oncology in Rectal cancer – What is the evidence-based that 'we' have created?</p> <p>Evidence from meta-analyses (short course, radiochemotherapy, adjuvant chemotherapy) D. Sebag-Montefiore (UK)</p> <p>Evidence from population based registry (EURECCA) C. van de Velde (NL)</p>
08:45 – 10:00 Symposia	<p>Head & Neck cancer- What is the evidence that is being created right now? - The best of clinical trials</p> <p>The new disease: How to deal with the HPV positive and not to leave the HPV negative behind? L. Licitra (IT)</p> <p>Dose conformity and escalation: Did we really decrease side effects and increase tumor control? C. Nutting (UK)</p> <p>Will concomitant chemo-radiation still be used in the area of EGFR inhibitors? K. Harrington (UK)</p> <p>How should we manage patients with locoregionally advanced head and neck cancer who are not suitable for chemo-radiotherapy? B. O'Sullivan (CA)</p>	<p>ESTRO-ESSO Joint session</p> <p>Rectal cancer - What is the evidence-based that is being created right now? - The best of clinical trials</p> <p>Testing new treatment combination G. Lammering (NL)</p> <p>Only preoperative loco-regional and systemic therapy in rectal cancer - the randomized RAPIDO trial B. Glimelius (SE)</p> <p>Testing new subgroup based tailored strategies M.A. Gambacorta (IT)</p>
10:00 – 10:30	Coffee break	
10:30 – 11:45	Head & Neck cancer - Vision for the future: What 'we' will	ESTRO-ESSO

Symposia	<p>ask for in the new grant applications?</p> <p>Biological and image guided adaptive radiotherapy : Understanding and taking advantage of the tumor biology RH. Brakenhoff (NL)</p> <p>Localize the enemy: Imaging in H&N cancer V. Gregoire (BE)</p> <p>Adaptive radiation treatment of head and neck cancer in the future – advanced treatment planning and delivery C. Grau (DK)</p>	<p>Joint session</p> <p>Vision for the future: What ‘we’ will ask for in the new grant applications? - Translational research / High technology</p> <p>Adaptive radiotherapy in rectal cancer: future or futile? C. Marijnen (NL)</p> <p>Adaptive radiotherapy by molecular imaging changes K. Haustermans (BE)</p> <p>Adaptive radiotherapy by predictive biological markers C. Roedel (DE)</p>
11:45– 13:00	<p>Anniversary Plenary Lecture Honorary Physicist Award Lecture</p>	
13:00 – 14:45	<p>Lunch, Satellite Symposia, Poster Viewing</p>	
14:45 – 16:15 Symposia	<p>New frontiers in metastatic cancers</p> <p><i>Session developed in collaboration with ASCO and ESMO</i></p> <p>New molecular targets for advanced lung cancer JC Soria (FR)</p> <p>Improving the outcome with curative high precision radiotherapy for metastatic patients? E. Lartigau (FR)</p> <p>Abscopal immune response linked to radiotherapy S. Formenti (USA)</p> <p>Can small doses of radiation enhance chemotherapy in advanced patients? V. Valentini (IT)</p>	<p>Proffered papers on Head and Neck cancer</p>
16:15 – 16:45	<p>Coffee break</p>	
16:45 – 18:00 Symposia	<p>ESTRO – JASTRO Joint symposium</p> <p>What is the level of evidence needed in Particle Therapy?</p>	<p>Proffered papers on Rectal cancer</p>

	<p>Debate: We do not need randomized trials to demonstrate that proton is superior to X-rays therapy</p> <p>For the motion: H. Sakurai (Japan)</p> <p>Against the motion: W Robert Lee (USA)</p> <p>Tumor sites to be selected for comparison of carbon ions vs protons? H Tsujii (JPN)</p> <p>What tumor sites should be selected for randomized trials? J. Debus (DE)</p>	
18:00 – 19:30	Poster Reception	

TUESDAY, 10 MAY 2011

	ESTRO Anniversary track	ESTRO Anniversary track
08:00 – 08:45 Symposia	<p>30 years of radiation oncology in Lung cancer- What is the evidence that 'we' have created? – Update on randomized trials and Meta-analyses</p> <p>The controversy of modified fractionation regimens M. Saunders (UK)</p> <p>Induction vs. concomitant radiochemotherapy In lung cancer C. Le Pechoux (FR)</p>	<p>30 years of radiation oncology in Breast cancer - What is the evidence that 'we' have created? – Update on randomized trials and Meta-analyses</p> <p>Update of Oxford analysis – a critical evaluation C. Taylor (UK)</p> <p>Radiation-related heart disease following treatment for breast cancer S. Darby (UK)</p>
08:45 – 10:00 Symposia	<p>ESTRO-ESTS-ERS Joint session</p> <p>Lung Cancer - What is the evidence that is being created right now? - The best of clinical trials - Early stage NSCLC</p> <p>Limited resection H. J. Hansen (DK)</p> <p>Stereotactic RT: The new standard for high-risk patients with NSCLC F. Lagerwaard (NL)</p> <p>Radiofrequency ablation T. DeBaere (FR)</p> <p>Role of adjuvant chemotherapy J-P Sculier (BE)</p> <p>Radiobiology and molecular response imaging in hypofractionation J. Bussink (NL)</p>	<p>Breast cancer - What is the evidence that is being created right now? - The best of clinical trials</p> <p>Update and status report on hypofractionation and acceleration (START and Canadian study) <i>Speaker tbc</i></p> <p>Update and status of Boost trial H. Bartelink (NL)</p> <p>Evaluation of radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 25-year update of the Danish Breast Cancer Cooperative Group DBCG 82b&c Trial M. Overgaard (DK)</p>
10:00 – 10:30	Coffee break	
10:30 – 11:45	ESTRO-ESTS-ERS	Breast cancer - Vision for the future: What 'we' will ask

Symposia	<p>Joint session Lung Cancer - Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology</p> <p>Bio-imaging for dose-escalation in NSCLC D. De Ruyscher (NL)</p> <p>Protons compared to X-IMRT compared to 3D in locally advanced NSCLC R. Komaki (USA)</p> <p>Biological Prediction for Molecular Targeting in Radiotherapy of NSCLC M. Baumann (DE)</p>	<p>for in the new grant applications? - Translational research / High technology</p> <p>Molecular prediction AL. Børresen-Dale (NO)</p> <p>Proper target / Partial breast J. Yarnold (UK)</p> <p>Interaction with systemic therapy A. Fourquet (FR)</p>
11:45 – 13:00 Award Lecture	<p>Iridium Award Lecture J. Battermann (NL)</p> <p>Varian-Physics, Accuray-Physics and Jack-Fowler Physics award lectures</p>	
13:00 – 14:45	Lunch, Satellite Symposia, Poster Viewing	
14:45 – 16:15 Symposia	<p>ESTRO – ASTRO Joint symposium</p> <p>How high precision technology will change our life</p> <p>High tech radiation therapy: where are the limits? B. Slotman (NL)</p> <p>Targeting concepts: Spatial, molecular, physiologic, temporal T. Rich (USA)</p> <p>What is the clinical benefit of 4D adaptive radiotherapy? C. Rasch (NL)</p> <p>Adaptive treatment with molecular imaging D. Zips (DE)</p>	Proffered papers on Lung cancer
16:15 – 16:45	Coffee break	
16:45 – 18:00 Symposia	<p>ESTRO – CARO Joint symposium</p>	Proffered papers on Breast cancer

	<p>Translating research in imaging into clinical practice</p> <p>From genomics to individualized treatment B. Wouters (CA)</p> <p>Translating Molecular imaging into the clinic: from mouse to man P. Lambin (NL)</p> <p>Dose painting: how and for which tumors? V. Khoo (UK)</p> <p>Real time IGART with linac MR hybrid G. Fallone (CA)</p>	
19:00	Social evening	

WEDNESDAY, 11 MAY 2011

	ESTRO Anniversary track	ESTRO Anniversary track
08:00 – 08:45 Symposia	<p>30 years of radiation oncology in Prostate cancer - What is the evidence-based that 'we' have created?</p> <p>Dose escalation: how big is the advantage? D. Dearnaley (UK)</p> <p>Prostate cancer: adjuvant androgen deprivation therapy in the era of new technologies and dose escalation M. Bolla (FR)</p> <p>Salvage or adjuvant radiation therapy after prostatectomy T. Wiegel (DE)</p>	<p>30 years of radiation oncology & Normal tissue - What is the evidence that 'we' have created?</p> <p>Fractionation: clinical application of radiobiological knowledge M. Joiner (USA)</p> <p>Pathogenesis and repair of normal tissue damage W. Doerr (DE)</p>
08:45 – 10:00 Symposia	<p>ESTRO-EAU Joint session</p> <p>Prostate Cancer - What is the evidence-based that is being created right now? - The best of clinical trials</p> <p>Options and outcome of salvage treatment after radiotherapy G. Ahlgren (SE)</p> <p>Will our guidelines be reshaped by: robotic surgery? V. Ficarra (IT)</p> <p>Will our guidelines be reshaped by: particle beams? A. Zietman (USA)</p> <p>Will our guidelines be reshaped by: brachytherapy? P. Hoskin (UK)</p>	<p>Normal tissue - What is the evidence-based that is being created right now?</p> <p>Radiation fibrosis and strategies for inhibition of this process MC Vozenin-Brotans (FR)</p> <p>Vascular mediated normal tissue damage and strategies for inhibition of this process M. Hauer-Jensen (USA)</p> <p>Oxidative stress in radiation-induced normal tissue damage and strategies for inhibition of this process <i>Speaker tbc</i></p>
10:00 – 10:30	Coffee break	
10:30 – 11:45 Symposia	<p>ESTRO-EAU Joint session</p> <p>Prostate Cancer - Vision for the future: What 'we' will ask for</p>	<p>Normal tissue - Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology</p>

	<p>in the new grant applications? - Translational research / High technology</p> <p>Beyond stage, PSA and Gleason Score: genetic prognostic factors J. Schalken (NL)</p> <p>Beyond stage, PSA and Gleason Score: Wait and see randomised trial: A. Widmark (SE)</p> <p>Beyond stage, PSA and Gleason Score: biological and functional imaging J. Barentsz (NL)</p>	<p>Prediction and prognosis of normal tissue radiation injury J. Alsner (DK)</p> <p>Stem cell / progenitor cell therapy to inhibit radiation injury R. Coppes (NL)</p> <p>Understanding and manipulating cytokine networks involved in development of radiation injury <i>Speaker tbc</i></p>
11:45 – 12:45 Plenary Lecture	Honorary Members Award lectures	
12:45 – 14:30	Lunch, Satellite Symposia, Poster Viewing	
14:30– 16:00 Symposia	<p>ESTRO-ESMO-ESSO-ECCO Presidential symposium Clinical Oncology: The future of Radiotherapy, Medical Oncology and Surgical Oncology</p> <p>Clinical Oncology: The future of Radiotherapy and Medical Oncology, Lancet April 18, 1981. Status then and now (30-years later) – did the wishes come true? M. Peckham (UK)</p> <p>Clinical Oncology in Europe 2011 and beyond D. Kerr (UK)</p> <p>Clinical Oncology in Europe 2011 and beyond P. Naredi (SE)</p>	<p>Proffered papers on Prostate cancer & Gynecological cancer</p>
16:00 – 16:30	Coffee break	
16:30 – 17:45 Symposia	<p>ESTRO-ESMO-ESSO-ECCO Presidential symposium Clinical Oncology: The future of Radiotherapy, Medical Oncology and Surgical Oncology</p> <p>Clinical Oncology in Europe 2011 and beyond J. Bourhis (FR)</p>	<p>Proffered papers on normal tissue</p>

	Clinical Oncology in Europe 2011 and beyond M. Baumann (DE)	
--	--	--

THURSDAY, 12 MAY 2011

	ESTRO Anniversary track	ESTRO Anniversary track
08:00 – 08:45 Symposia	<p>30 years of radiation oncology in Gynecological cancer - What is the evidence that 'we' have created? – Update on randomized trials and Meta-analyses</p> <p>Cervix Cancer, definitive chemoradiation (chemo-surg-rad) G. Thomas (CA)</p> <p>Cervix cancer: Brachytherapy dose/rate/fractionation C. Haie-Meder (FR)</p> <p>Post-operative adjuvant therapy for endometrial cancer. Recent trials and the way forward PR Blake (UK)</p>	<p>Testis</p> <p>How we learnt to cure testicular cancer- the road to 2011 M. Williams (UK)</p> <p>The problems caused by curing testicular cancer and survivorship S. Fossa (NO)</p> <p>Learning lessons from the past: the path forward and new opportunities R. Huddart (UK)</p>
08:45 – 10:00 Symposia	<p>ESTRO-ESGO Joint symposium</p> <p>Gynecological Cancer - What is the evidence-based that is being created right now?- The best of clinical trials</p> <p>Cervix and Endometrium Cancer: Imaging/Contouring and Technology (IMRT, IGRT) M. Powell (UK)</p> <p>Cervix Cancer: Image guided adaptive brachytherapy EMBRACE J. Lindegaard (DK)</p> <p>Cervix Cancer: Ongoing trials and the GCIG initiative H. Kitchener (UK)</p> <p>Endometrial Cancer (adjuvant RT/combined): ongoing trials C. Creutzberg (NL)</p>	<p>Ethical issues in the management of oncology patients</p> <p>Interactive session Moderators: K. Benstead (UK) and S. Guglani (UK)</p> <p>Ethical issues/ challenges/ principles in managing cancer patients</p> <p>Cases containing conflict - Individual rights against goals of medicine - Therapeutic momentum against resource constraints</p> <p>Conclusion</p>
10:00 – 10:30	Coffee break	
10:30 – 11:45 Symposia	<p>ESTRO-ESGO Joint symposium</p>	<p>ESTRO - EANM Joint symposium</p>

	<p>Gynecological Cancer - Vision for the future: What 'we' will ask for in the new grant applications? - Translational research / High technology</p> <p>New anti-viral approach in cervical carcinoma E. Deutsch (FR)</p> <p>Cervix: Technology translational research R. Pötter (AT)</p> <p>Technological and translational developments in endometrial cancer treatment: molecular data and image guidance R. Nout (NL)</p> <p>What's new in sentinel lymph node detection in vulvar cancer AGJ van der Zee (NL)</p>	<p>Imaging</p> <p>PET in Oncology in 2011: where are we coming from? Review of the equipments, tracers, indications, over the last 10-20 years. W. Vogel (NL)</p> <p>PET in radiation oncology in 2011: where are we? Use of PET (different tracers) for target volume selection and delineation. A. Chiti (IT)</p> <p>PET in Oncology in 2015: where are we going to? A projection of how we could factor PET in RO in the coming future. X. Geets (BE)</p>
--	--	---